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Abstract We previously identiﬁed regulator of G-protein
signaling 5 (RGS5) among several genes expressed by
tumor-derived endothelial cells (EC). In this study, we
provide the ﬁrst in vivo/ex vivo evidence of RGS5 protein
in the vasculature of ovarian carcinoma clinical specimens
and its absence in human ovaries. Consistent with this, we
show higher amounts of Rgs5 transcript in EC isolated
from human cancers (as opposed to normal tissues) and
demonstrate that expression is sustained by a milieu of
factors typical of the proangiogenic tumor environment,
including vascular endothelial growth factor (VEGF) and
basic ﬁbroblast growth factor (FGF-2). Supporting these
ﬁndings, we show elevated levels of Rgs5 mRNA in the
stroma from strongly (as opposed to weakly) angiogenic
ovarian carcinoma xenografts and accordingly, we also
show more of the protein associated to the abnormal vas-
culature. RGS5 protein predominantly colocalizes with the
endothelium expressing platelet/endothelial cell adhesion
molecule-1 (PECAM-1/CD31) and to a much lesser extent
with perivascular/mural cells expressing platelet-derived
growth factor receptor-beta (PDGFR-b) or alpha smooth
muscle actin (aSMA). To toughen the relevance of the
ﬁndings, we demonstrate RGS5 in the blood vessels of
other cancer models endowed with a proangiogenic envi-
ronment, such as human melanoma and renal carcinoma
xenografts; to the contrary, it was undetectable in the
vasculature of normal mouse tissues. RGS5 expression by
the cancer vasculature triggered and retained by the pro-
angiogenic microenvironment supports its exploitation as a
novel biomarker and opens the path to explore new pos-
sibilities of therapeutic intervention aimed at targeting
tumor blood vessels.
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Introduction
Vascularization is required for tumor growth and metasta-
sis, and constitutes a key step in the control of cancer
progression [1, 2]. Experimental evidence correlates tumor
vascularization with high malignancy, and elevated levels
of angiogenic factors—such as vascular endothelial growth
factor (VEGF) and ﬁbroblast growth factor (FGF-2)—relate
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123to poor prognosis [3]. Tumor-induced vessels are structur-
ally abnormal and differ from normal vasculature. They are
heterogeneous in organization, structure, and function, and
branch irregularly originating a vasculature unevenly dis-
tributed and chaotic [4]. These abnormalities reﬂect their
pathological nature and underline the importance of devel-
oping novel therapeutic strategies directed against the
vascular elements of the tumor stroma in order to selectively
target tumor vasculature and inhibit tumor growth [5].
To this end, in a previous investigation aimed at com-
paring the gene expression proﬁles of endothelial cells
(EC) from tumor and normal human tissues, we demon-
strated distinct transcriptional features characterizing the
ECs [6]. Regulator of G-protein signaling (RGS) 5 was
listed among the transcripts expressed by the EC coming
from the tumor environment.
RGS5 is a member of the RGS family of multifunctional
GTPase-activating proteins (GAPs) known to negatively
regulate the signaling of G-protein coupled receptors
(GPCR); it is currently unknown which pathways are
regulated by RGS5. In RGS5-transfected smooth muscle
cells and ﬁbroblasts, the capability of RGS5 to attenuate
the signaling triggered by proteins mediating vascular
functions—such as angiotensin II (AngII), endothelin-1
(ET-1), and sphingosine-1-phosphate (S1P) [7–9]—is
suggestive of a possible involvement of RGS5 in blood
vessel maturation and homeostasis. Rgs5 mRNA expres-
sion was shown to be dynamically regulated during the
healing of cutaneous wound and hormone-induced ovula-
tion of mice [10]. In mouse models of pancreatic islet
carcinogenesis Rgs5 transcript was found in the blood
vessels of the late-stage insulinomas but not of the normal
or hyperplastic pancreatic islet [10, 11], and its deletion
(RIP1-Tag5 crossed to RGS5-deﬁcient mice) was shown to
normalize the otherwise chaotic and disorganized tumor
vasculature [12].
All these observations strongly point to the importance
of RGS5 in angiogenesis and for the tumor blood vessels
alterations; despite so, very little is known about its patho-
physiological involvement in human cancer.
In light of this consideration, we investigated the con-
tribution of RGS5 to tumor angiogenesis and vasculature
using ovarian carcinoma as a paradigm. Most importantly,
given that in the current literature the information relies
solely on gene expression, we evaluated the expression/
localization of the encoded protein.
In this study, we show for the ﬁrst time the RGS5 pro-
tein as a marker of cancer vasculature, in both human
clinical specimens and tumor xenografts. We show the
involvement of RGS5 in the vascular remodeling occurring
within the tumor’s angiogenic microenvironment, and its
predominant colocalization with the endothelium lining the
tumor blood vessels.
Our ﬁndings underline the importance of RGS5 in
human cancer and thus are of biomedical relevance. The
exploration of whether RGS5 may serve as a biomarker or
as a therapeutic target of cancer vasculature will provide an




Human EC from carcinomas (ovarian and renal) and non-
neoplastic tissue specimens (adrenal glands and skin) were
isolated and cultured as described [6]. The expression of
platelet endothelial cell adhesion molecule-1 (PECAM-1/
CD31) and von Willebrand factor (vWF), the ability to
uptake low-density lipoproteins (LDL) and to form cord-
like structures were assayed in order to verify the endo-
thelial origin of the cells (as described in [6]). Smooth
muscle cells from umbilical artery (uaSMC) were pur-
chased from Clonetics (Clonetics-BioWhittaker) and
cultured in SmBM Growth Medium following the manu-
facturer’s protocol. HuFb and Malme-3 human ﬁbroblasts
were purchased from ATCC and grown in RPMI-1640
medium plus 10% FBS. All cells were assayed in the
presence of 10 ng/ml of VEGF and EGF, and 2 ng/ml of




Female NCr-nu/nu mice, 6–8 weeks old, were obtained
from Harlan. The mice were maintained under speciﬁc
pathogen-free conditions, housed in isolated ventilated
cages, and handled using aseptic procedures. Procedures
involving animals and their care were conducted in con-
formity with institutional guidelines, in compliance with
national (Legislative Decree 116 January 27, 1992,
Authorization n.169/94-A issued December 19, 1994, by
Ministry of Health), and international laws and policies
(EEC Council Directive 86/609, OJ L 358.1, December 12,
1987; Standards for the Care and Use of Laboratory Ani-
mals, United States National Research Council, Statement
of Compliance A5023-01, 1996).
Tumor xenografts
Human xenografts of 1A9-VS1 and 1A9-VAS3 ovarian
carcinoma, RXF393 renal carcinoma, and WM1552/5p
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123melanoma were obtained by subcutaneous injection of
10 9 10
6 cells in the ﬂanks of NCr-nu/nu mice. 1A9-VS1
(high VEGF) and 1A9-VAS3 (low VEGF) cells were
previously originated [13]. RXF393 cells [14] were kindly
provided by H. Fiebig (Freiburg, Germany). WM1552/5p
cells were selected by A. Silini upon serial transplantations
of subcutaneously grown tumors from WM1552C mela-
noma cells, kindly provided by M. Herlyn (Philadelphia,
PA, USA) [15].
Microdissection of stroma from 1A9-VS1 and 1A9-VAS3
ovarian carcinoma xenograft
Hematoxylin-stained sections (10 lm) from frozen tumor
tissue were dissected with the PALM Microlaser System
(Carl Zeiss); stroma was separated from the parenchyma
without selecting any particular type of component (ECs,
ﬁbroblasts, etc.) and immediately lysed. RNA extraction
and real-time PCR were performed as described below.
Gene expression studies
RNA and real-time PCR
Total RNA was isolated with RNeasy
 Micro Kit (Qiagen)
and converted to cDNA with random hexamers (Archive
Kit, Applied Biosystems). Gene expression was analyzed
by real-time PCR using TaqMan
 Gene Expression Assay
(Applied Biosystems). Statistical analysis by unpaired two-
tailed t test and non-parametric Mann–Whitney test was
performed on the deltaCt (dCt) values to compare the
expression of RGS5 in EC isolated from tumor specimens
versus normal tissues, and in microdissected stroma from
1A9-VS1 versus 1A9-VAS3 xenografts. Relative expres-
sion was referred to the sample with the highest dCt and




EC were grown onto coverslips, ﬁxed (4% paraformalde-
hyde), permeabilized (0.1% Triton X-100), and stained for
RGS5 as speciﬁed below. Coverslips were mounted onto
glass slides after DAPI (0.6 lg/ml) counterstain.
Tumor xenografts
Cryostat sections (8 lm) were thawed, ﬁxed (acetone),
blocked (3% rabbit serum), and stained for 1 h with goat-
anti-human RGS5 (1:250, Santa Cruz Biotechnology).
Rinsed sections were incubated with Alexa Fluor 488
rabbit-anti-goat (1:800, Molecular Probes). Additionally,
sections were double/triple stained for RGS5 together with
rat-anti-mouse CD31 (1:50, BD Pharmingen, clone-
MEC13.3) or rat-anti-mouse CD140b/PDGFR-b (1:500,
eBioscience, cloneAPB5) or Cy3-conjugated anti-mouse
aSMA (1:200, Sigma), and with secondary antibodies
Alexa Fluor 350 goat-anti-rat (1:200, Molecular Probes) or
TRITC rabbit-anti-rat (1:200, Sigma) as appropriate.
Clinical specimens
Tissue sections were handled as described for the tumor
xenografts with the exception of assaying serial sections by
single color imaging to investigate RGS5, aSMA, and
CD31 (Alexa Fluor 488-conjugated mouse-anti-human
CD31; 1:100, BD Pharmingen, cloneM89D3). Tissue sec-
tions were from patients who underwent surgery at the San
Gerardo Hospital, Monza (Italy). Ovarian carcinoma
specimens were collected at time of the ﬁrst debulking
surgery from three patients [FIGO stage I and II (n = 2)]
that did not receive neoadjuvant chemotherapy, and from
one patient relapsing after surgery and chemotherapy. Non-
neoplastic ovaries (n = 3) were from postmenopausal
patients who underwent hysterectomy and bilateral sal-
pingo-oophorectomy for genital prolapse. Tissues were
immediately ﬂash-frozen. The research was approved by
the relevant ethics committees and all human participants
gave written informed consent.
Fluorescence imaging: quantitative assessment of RGS5
protein expression
RGS5 ﬂuorescence signal was expressed as ‘‘area density’’
as described [17] Brieﬂy, tissue sections stained for RGS5
(or only with the secondary antibody) were viewed with a
109 objective lens magniﬁcation by the BX61 microscope
(Olympus), and digital images captured and converted into
8-bit grayscale images using ImageJ software
http://rsbweb.nih.gov/ij/. The ‘‘area density’’ was calcu-
lated by dividing the number of RGS5 positively stained
pixels (i.e., with brightness greater than an arbitrary
threshold) by the number of pixels comprising the entire
sectional area. The threshold distinguishing the ‘‘RGS5-
positive signal’’ was the brightness value below which
99% of pixels fell in the negative control.
Four human ovarian carcinoma specimens versus three
non-neoplastic ovaries, and three 1A9-VS1 versus three
1A9-VAS3 tumors were examined for RGS5 expression.
At least three images were quantiﬁed for each sample
(n C 9 sectional areas) and differences in the ‘‘area den-
sity’’ between the two groups were evaluated by unpaired
two-tailed t test and non-parametric Mann–Whitney test;
p values\0.05 were considered statistically signiﬁcant.
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of ﬂuorophores
Double- and triple-stained sections of tumor xenografts
were examined with the Olympus BX61 epiﬂuorescence
microscope, using the appropriate ﬁlter-set for the different
ﬂuorochrome characteristics. Digital images from the dif-
ferent excitation wavelengths were captured with
ColorView II Soft Imaging System digital color camera
(Olympus) then co-registered using Adobe Photoshop
software (Adobe Systems) to combine multiple colors into
a single ﬁnal image (merge) showing overlapping, ﬂuo-
rescently labeled structures (RGS5, CD31, aSMA,
PDGFR-b).
Laser scanning confocal microscopy: colocalization
of ﬂuorophores
Selected multiple-labeled specimens were examined by
confocal microscopy to reveal colocalization. Sections
were scanned with blue diode, argon-ion, and green
helium–neon lasers (405-, 488-, and 543-nm spectral lines,
respectively) by sequential scanning and detection mode to
eliminate possible bleed-through effect. The images were
acquired with a 639 objective lens magniﬁcation by the
Zeiss LSM 510 Meta confocal microscope (Carl Zeiss).
Results
RGS5 expression in human tumor-derived endothelial
cells and its modulation by proangiogenic factors
Our previous microarray analysis investigation—aimed at
ﬁnding novel markers of tumor vasculature—listed RGS5
among the genes highly expressed by tumor-derived EC
[6]. In the present study, primary cultures of endothelial
cells were investigated by real-time PCR. We demonstrate
a statistically signiﬁcant higher level of Rgs5 transcript in
EC isolated from human carcinomas (mostly ovarian) in
comparison to EC isolated from non-neoplastic tissue
(adrenal glands and skin). As shown in Fig. 1a, the relative
expression of Rgs5 mRNA is at least ten times higher in
respect to normal tissue-derived EC, and also to commer-
cially available human smooth muscle cells and ﬁbroblasts
(that performed as the normal tissue-derived EC).
To mimic the milieu in which the EC are embedded
within a solid tumor’s microenvironment, stromal cells
were cultured with factors acknowledged to be typical of
the cancer/angiogenic environment, such as VEGF, FGF-2,
and EGF. We demonstrate that the removal of such an
environment from the tumor-derived EC results in a robust
decrease of Rgs5 mRNA expression; as shown in Fig. 1b, a
diminished amount of RGS5 transcript is consistently
measured in all the EC evaluated.
The primary cultures of EC express the protein encoded
by RGS5 (Fig. 1c), in addition to forming cord/tubular
structures, uptaking LDL, expressing vWF and PECAM-1/
CD31, typical features of endothelial cells.
These results demonstrate the expression of RGS5 by
EC isolated from human cancer specimens that is dynam-
ically modulated by the surroundings, and in particular
elicited by a milieu of proangiogenic factors, suggesting
that in an in vivo setting its expression by the cancer
vasculature is sustained by the microenvironment.
RGS5 protein expression in the cancer vasculature
of human clinical specimens
Sections from ovarian carcinomas and non-neoplastic
ovaries (patients’ biopsies) were investigated to assess
RGS5 protein by immunoﬂuorescence. All the cancer
specimens stain positive for RGS5 (Fig. 2a, b), whereas no
clearly visible signal is detectable in any of the ovaries
(Fig. 2a). Imaging analyses reveal that RGS5 ﬂuorescence
covers 7.3% of the area in ovarian carcinoma specimens
and less than 1% in healthy ovaries (Fig. 2b).
RGS5 staining clearly excludes the parenchyma
(Fig. 2a); the pattern of expression being reminiscent of
vessel-like structures (Fig. 2b). Accordingly, serial sec-
tions of the same specimens indicate that RGS5
positivity resembled that of CD31 and aSMA (Fig. 2c),
markers of vascular endothelium and perivascular mural
cells.
These results show the expression of RGS5 protein by
the vasculature of ovarian carcinoma clinical specimens
and not by the ovaries, which is suggestive of RGS5 as a
marker of cancer vasculature, which expression is trig-
gered/sustained by the tumor microenvironment.
RGS5 mRNA and protein expression in the vasculature
of strongly versus weakly angiogenic tumor xenografts
RGS5 was investigated in an experimental in vivo setting
where the same tumor type is endowed with either high or
low angiogenic potential: human ovarian carcinoma cells
moderately expressing VEGF, FGF-2, and PlGF (1A9-
VAS3) and their isogenic variant (1A9-VS1) transfected to
over-express VEGF, such that high amounts are measured
in the plasma of tumor-bearing mice [13], as occurs in
ovarian cancer patients [18]. The vasculature of 1A9-VS1
xenografts abounds of abnormally dilated blood vessels
and is quite heterogeneous, as opposed to the weakly
angiogenic 1A9-VAS3 tumors comprising the same num-
ber of blood vessels but displaying a rather homogeneous,
less abnormal vascular network [13].
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from both tumor variants; most importantly the amount of
transcript is statistically different (mean dCt 8.6 vs. 12) and
much higher in the stroma of 1A9-VS1 (Fig. 3a).
The expression of RGS5 protein is marked in both xe-
nografts and clearly excludes the parenchyma (Fig. 3b) as
already shown for the clinical specimens (Fig. 2). The
staining pattern of RGS5 is evocative of the different
vasculature, one being heterogeneous in distribution and
diameters (1A9-VS1) and the other having a more homo-
geneous network (1A9-VAS3). Protein was quantiﬁed and
is twofold higher in the VEGF-rich tumor environment;
RGS5 ﬂuorescence covers 4.6% of the sectional area in
1A9-VS1 and only 2.4% in 1A9-VAS3 (Fig. 3b), the dif-
ference being statistically signiﬁcant.
Altogether, these results show the RGS5 relationship
with the abnormal vasculature of the 1A9-VS1 tumor xe-
nografts triggered/sustained by the microenvironment’s
proangiogenic rich milieu and are suggestive of the RGS5
functional implication in the abnormal remodeling of blood
vessel.
RGS5 protein expression by the endothelium of ovarian
carcinoma xenografts
RGS5 protein was investigated together with the EC mar-
ker CD31, to provide an in vivo understanding of the
vessel-associated cell source. The staining pattern of RGS5
and CD31 is pretty much identical (Fig. 4a, b), consistent
with the overlapping of colors in the merge image
(Fig. 4c). Their co-expression was conﬁrmed by confocal
microscopy. Colocalization of RGS5 with CD31 is
revealed in double-stained sections (Fig. 4f) as well as in
triple-stained sections (Fig. 4i), where colocalization of
RGS5 with CD31 is shown in areas rich in both CD31- and
aSMA-positive vascular structures.
These results demonstrate that the endothelium lining
the blood vessels of human ovarian cancer xenografts
Fig. 1 RGS5 expression by human endothelial cells (EC). a Rgs5
mRNA is much more expressed in tumor-than in normal tissue-
derived EC. EC—isolated from human carcinomas or normal tissue
specimens—were grown in presence of the proangiogenic factors
VEGF, FGF-2 and EGF and investigated to assess Rgs5 mRNA by
real-time PCR. Statistical analysis evaluated the dCt values. The y-
axis indicates the relative expression: tumor-EC = black circles,
normal tissue-EC = white circles, lines = median values. Fibroblasts
(white squares) and uaSMC (white triangle) performed as the normal
tissue EC. b Rgs5 mRNA expression by tumor-derived EC is fueled
by angiogenic growth factors. Rgs5 mRNA was evaluated in tumor-
derived EC grown in presence of a tumor/angiogenic microenviron-
ment (as in a) and subsequent to its withdrawal. The arrows indicate
the declining of expression. c RGS5 protein is expressed by tumor-EC
growing in vitro. RGS5 protein (green, ﬁrst panel) in representative
EC isolated from an ovarian carcinoma specimen whose endothelial
origin was veriﬁed by positive staining for CD31 (green) and vWF
(red), by LDL uptake (red), by morphology (brightﬁeld) and cord
formation
RGS5 protein 1171
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expression by the vasculature of
human clinical specimens. In
human clinical specimens,
RGS5 protein is expressed in
ovarian carcinomas but absent
in non-neoplastic ovaries.
a Representative images (scale




(blue) from human ovarian
cancer specimens and non-
neoplastic ovaries. [Note that
the latter is negative for RGS5,
but positive for CD31 and
aSMA]. Demonstrative H&E
images are shown.
b Quantiﬁcation of protein
*p\0.05. Representative
images (scale bars 20 lm)
illustrating the positive RGS5





bars 100 lm) of serial sections
(top vs. bottom) from ovarian
carcinoma specimens stained
for RGS5, CD31, aSMA
Fig. 3 RGS5 mRNA and protein expression by human ovarian
carcinoma xenografts: VEGF-rich compared to VEGF-poor tumors.
a Rgs5 mRNA is more expressed in the stroma of 1A9-VS1 than 1A9-
VAS3 tumors. Stroma was microdissected from 1A9-VS1 and 1A9-
VAS3 xenografts (n = 10 and n = 11 tumors, respectively) and Rgs5
expression assessed by real-time PCR. Statistical analysis evaluated
the dCt values: unpaired two-tailed t test p = 0.017, non-parametric
Mann–Whitney test p = 0.02. The y-axis indicates the relative
expression referred to the stroma sample with the lowest but
detectable expression. b RGS5 protein is more expressed in 1A9-
VS1 than 1A9-VAS3 tumors. Representative images (scale bars
200 lm) illustrating tissue sections immunostained for RGS5 (green).
Quantiﬁcation of protein:*p\0.05. For each tumor variant, at least
nine section-images were examined
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clinical specimens and as revealed by the in vitro results.
RGS5 protein expression by the vascular endothelium
of different tumor types
Having demonstrated that RGS5 is expressed by the EC of
abnormal tumor vasculature in ovarian cancer fueled by the
angiogenic microenvironment, we assessed whether the
same could be observed in other angiogenic tumor models,
namely human renal carcinoma RXF393 and melanoma
WM1552/5p xenografts. These tumors inherently produce
human VEGF (measurable in the plasma of tumor-bearing
mice) and moderately express also FGF-2 or PDGF-B.
We demonstrate the expression of RGS5 protein and its
association with the endothelium in both these xenografts.
The vascular network is different between the two tumors
(Fig. 5b, e), and RGS5 recapitulate the same staining
patterns (Fig. 5a, d); indeed the merge images show a
great degree of RGS5-CD31 overlap in both RXF393 and
WM1552/5p (Fig. 5c, f). Moreover, triple-stained sections
conﬁrm that RGS5 overlaps with CD31 (Fig. 5i) rather
than with aSMA (Fig. 5l). Altogether, these results pro-
vide strong evidence that the endothelium lining the blood
vessels of cancer expresses RGS5. Conversely, no clear
signal of RGS5 staining in association with the vascula-
ture of normal mouse organs is visible (supplementary
material 1).
Fig. 4 RGS5 protein is expressed by vascular endothelium of human
ovarian carcinoma xenografts. Representative images illustrating
1A9-VS1 tissue sections co-stained with RGS5 (green), CD31 (blue)
and/or aSMA (red). a–c Epiﬂuorescence microscopy (scale bars
100 lm); the merge image (c) shows RGS5-CD31 overlap (light
blue). d–l Confocal microscopy (scale bars 20 lm) of double- (d–
f) and triple- (g–l) stained sections. Images show colocalization of
RGS5 with CD31 (f and i, white arrows) mostly excluding aSMA (l,
yellow arrows)
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comprising the tumor blood vessels, too
Given that the expression of Rgs5 mRNA had been asso-
ciated with mural cells such as pericytes/vSMC in tumors
of RIP1-Tag2 mice [11], we double stained the human
xenografts either with RGS5 and aSMA or with RGS5 and
PDGFR-b. Representative merge images show that RGS5
protein overlaps to a certain extent with aSMA and with
PDGFR-b positive staining (Fig. 6c, i). The expression of
RGS5 by PDGFR-b and aSMA-positive cells was con-
ﬁrmed by confocal microscopy. As shown in Fig. 6, RGS5
staining can colocalize with PDGFR-b (Fig. 6l) and also
with aSMA (Fig. 6f), signifying that the mural cells asso-
ciated with the abnormal tumor vasculature are capable of
expressing RGS5.
Discussion
This study demonstrates RGS5 as a protein characterizing
the endothelium of human cancer, and involved in the
remodeling of the vasculature occurring during pathologi-
cal angiogenesis triggered by the tumor microenvironment.
Thus, our results open the path to explore new possibilities
to target/affect the cancer vasculature for therapeutic
intervention and to exploit novel molecules, which could
serve as clinical biomarkers.
RGS5 is one of the many modulators of GPCR signal-
ing, but the regulatory functions and the role remain to be
elucidated. Recently, in RIP1-Tag mice Rgs5 mRNA was
shown associated to the vascular bed of late-stage insuli-
nomas but not of the normal/hyperplastic pancreatic islets
[10, 11]; its ablation (RIP1-Tag5 crossed to RGS5 knock-
out mice) was shown to ‘‘normalize’’ the otherwise
abnormal, chaotic, and disorganized vasculature of insuli-
nomas [12]. These observations altogether suggest a key
role of RGS5 in the blood vessel remodeling occurring
during carcinogenesis. Despite this, its connection with
human cancer remains largely elusive.
We now show the RGS5 protein in the vasculature of
ovarian carcinoma clinical specimens and its absence in
non-neoplastic ovaries, suggestive of its involvement in the
malignant progression of human cancer. By focusing on the
protein, our results strengthen the currently published
observations pertaining to clinical specimens, which are
limited to in situ hybridization and refer to different cancer
types; Rgs5 mRNA was detected in sinusoidal endothelium
Fig. 5 RGS5 protein is expressed by vascular endothelium of human
melanoma and renal carcinoma xenografts. Representative images
illustrating WM1552/5p and RXF393 tissue sections co-stained with
RGS5 (green), CD31 (blue) and/or aSMA (red). a–f (scale bars
100 lm), RGS5-CD31 overlap (light blue) is shown for both tumors
in the merge images (c and f). g–l (scale bars 20 lm), note the great
overlapping of RGS5 to CD31 (i, white arrows) mostly excluding the
aSMA positive stain (l, yellow arrows) in the triple stained section
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liver [19], and likewise in renal cell carcinoma vasculature
as opposed to the adjacent kidney [20]. Consistent with the
in vivo results, we prove that human vascular cells growing
in vitro express RGS5, but most importantly we demon-
strate that the transcript is more highly expressed by
endothelial cells isolated from cancer specimens (mainly
ovarian but including a renal carcinoma) than from non-
neoplastic tissues. This observation conﬁrms our previous
gene expression proﬁling investigation, concerning a dif-
ferent collection of ECs, [6] that listed RGS5 among the
genes distinguishing ovarian carcinomas-derived EC, and
substantiate another microarray study similarly listing
RGS5 as one of the EC genes characterizing hepatocellular
carcinoma [19]. Altogether, these ﬁndings demonstrate
RGS5 as a marker of cancer-associated EC, suggesting the
possibility that it may serve as clinical biomarker.
All the observations point to a link between RGS5
expression and the environment in which the cancer-asso-
ciated EC are embedded, which is rich in proangiogenic
factors. To toughen this, we demonstrate that removing the
in vitro condition mimicking the proangiogenic tumor
microenvironment results in the robust decrease of RGS5
expression, thus making the EC isolated from human cancer
specimens less ‘‘abnormal’’ and closer to normal EC.
Coherent with our ﬁndings, in RIP1-Tag5 mice, murine
Rgs5 mRNA has been shown to be down-regulated in ‘‘less
angiogenic’’ insulinomas, which vasculature resembled that
Fig. 6 RGS5 protein is expressed by vascular mural cells. Repre-
sentative images illustrating 1A9-VS1 and RXF393 tissue sections
co-stained with RGS5 (green), and either aSMA or PDGFR-b (red).
a–c and g–i Epiﬂuorescence microscopy (scale bars 100 lm); the
merge images show the overlap (yellow) of RGS5-aSMA (c)o r
RGS5-PDGFR-b (i). d–f and j–l Confocal microscopy (scale bars
10 lm) show colocalization of RGS5 (white arrows) with aSMA
(f) or with PDGFR-b (l)
RGS5 protein 1175
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ings, we also demonstrate a signiﬁcantly higher transcript
expression by the stroma microdissected from ovarian car-
cinoma tumor xenograft endowed with high, as opposed to
low, angiogenic potential. In agreement, we show that the
RGS5 protein colocalizes with the endothelium, and most
importantly, is more abundant in the VEGF-rich xenografts
where the vasculature is irregular and vessels are dilated
whileitwasundetectableinthevasculatureofnormalmouse
organs. Altogether, these ﬁndings further consolidate the
implication of RGS5 in the abnormal vascular remodeling
occurring within the tumor and triggered by the proangio-
genic environment. A role perhaps less important in
physiologicalsituationssuchasdevelopmentalangiogenesis
given that RGS5-deﬁcient mice lack gross histopathological
signs of developmental defects and are fertile [12, 21].
It is well known that VEGF is central to the process of
angiogenesis [22]. Its expression has been correlated with
clinic-pathologic features and patients’ survival, and ele-
vated serum/plasma levels of VEGF have been described in
cancer patients, including ovarian carcinoma [18, 23]. In
the present study, high levels of VEGF circulated in the
bloodstream of mice bearing the strong proangiogenic
tumor xenografts (melanoma, renal, and ovarian carci-
noma), giving additional credit to a translation of our
results into a clinical situation.
Whether within the cancer microenvironment as a whole
the expression of RGS5 is directly induced by VEGF or,
though necessary VEGF may not be on its own sufﬁcient,
requiring the intricate surrounding remains to be elucidated.
Cancer vasculature is embedded in a milieu of soluble
growthfactors,andamongotherthings,affectedbyhypoxia.
HUVEC Rgs5 mRNA could not be induced by VEGF alone
(data not shown and [24]) but it increased under hypoxia
[24]; implying the need for a complex surrounding.
Accordingly, in this study, Rgs5 expression by EC is sus-
tained by the multi-factorial in vitro setting that includes
VEGF, FGF-2 and EGF, and likewise—although expressed
at high levels and circulating in the bloodstream of tumor-
bearing mice—VEGF is not the only proangiogenic factor
expressed by the tumor cells originating the different
xenografts.
VEGF is pivotal in eliciting angiogenesis, but emerging
evidence suggests that inhibition of VEGF signaling (the
primary target of therapeutics inhibiting angiogenesis) can
trigger molecules, such as FGF-2 to initiate a secondary
phase of tumor angiogenesis [25]. The identiﬁcation of
novel/alternative ways to target/affect tumor vasculature
will therefore be advantageous; hence our ﬁndings have
signiﬁcant potential for anticancer therapy as they pose the
basis to explore such a possibility.
The localization of RGS5 to the cells constituting the
blood vessels is a matter for debate. Rgs5 mRNA had been
either associated with CD31/CD34 positive vasculature in
human renal cell carcinoma [20] or established as a marker
of pericytes/vSMC rather than of EC in RIP1-Tag mice
tumors [9, 10, 26], predominantly related to immature
(PDGFR-b positivity) in respect to mature (aSMA or NG2
positivity) perivascular cells [11, 12]. All the in vivo
studies relied on transcript expression, making the precise
cellular localization very difﬁcult given the close associa-
tion of the different cells composing the blood vessels. Our
results provide a conclusive answer: by showing the
colocalization of RGS5 protein mainly with CD31 but also
with PDGFR-b and aSMA of ex vivo specimens from
melanoma, renal, and ovarian carcinoma xenografts, we
prove that RGS5 can be expressed by both endothelial and
pericytes/vSMC cells.
Endothelial and mural cells are implicated in regulating
tumor growth, and therefore both suggested as targets in
anticancer therapy aimed at disturbing tumor vasculature.
Multikinase inhibitors, such as sunitinib and sorafenib,
affecting both VEGF receptor-driven EC and PDGF
receptor-dependent pericytes, have recently been intro-
duced into clinical practice for the treatment of advanced
renal cell carcinoma and hepatocellular carcinoma [27, 28].
RGS5 expression in human clinical specimens, and its
speciﬁcity to cells comprising the tumor vasculature,
makes it a strong candidate for therapeutic intervention.
Strategies reverting tumor blood vessel abnormalities
(normalization) are regarded as promising anticancer
approaches aimed at improving the response to chemo-
therapy and reducing metastasis [29–31]. It has been shown
that ablation of RGS5 from the tumor microenvironment of
RIP1-Tag5 mice resulted in tumor blood vessel ‘‘normali-
zation’’ notably improving outcome in response to
immunotherapy [12]. Likewise, enhancement of therapeu-
tic effects has been seen when conventional chemotherapy
are administered in combination with anti angiogenic or
vascular affecting drugs [32–34]. The potential to enhance
the efﬁcacy of anti cancer strategies in the absence of
RGS5 deserves to be explored.
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